👶Pregnancy
Guanfacine is not considered a preferred medication for chronic hypertension in pregnancy, and outcome data for guanfacine exposure in pregnancy are limited. For ADHD, many experts recommend discontinuing guanfacine during pregnancy when possible due to limited data and the availability of non-medication supports. If exposure occurs, discuss risks and monitoring, and consider enrolling in the National Pregnancy Registry for ADHD Medications.🤱Breastfeeding
It is not known whether guanfacine is present in breast milk. If used during breastfeeding, monitor the infant for lethargy, poor feeding, and sedation. Decisions should weigh infant exposure risk, breastfeeding benefits, and maternal treatment benefits.👧Children & Adolescents (Under 18)
ADHD (extended-release, ages 6 to 17): Start 1 mg once daily at the same time each day (morning or evening). Titrate by no more than 1 mg per week based on response and tolerability. Target range commonly referenced: 0.05 to 0.12 mg/kg/day (or roughly 1 to 7 mg/day within age-based maximums). Maximums not evaluated above: monotherapy—children 6 to 12 years: 4 mg/day; adolescents 13 to 17 years: 7 mg/day. Adjunct to stimulants: doses above 4 mg/day have not been evaluated. If converting from IR to ER: discontinue IR and start ER using ER titration (do not convert mg-for-mg). Missed ER doses: if ≥2 consecutive doses missed, consider repeating titration. Discontinuation ER: taper by ≤1 mg every 3 to 7 days. ASD + ADHD (comorbidity, limited data, often IR in reports): dosing is individualized with slow increments and close monitoring for irritability. Tourette/tics (limited data, often IR): titration schedules exist in studies, commonly starting low at bedtime and increasing in small steps every few days toward a divided-dose total, with careful monitoring of sedation and vitals.👴Older Adults (65+)
Avoid as a routine antihypertensive in adults ≥65 per Beers Criteria due to CNS adverse effects and risk of bradycardia/orthostatic hypotension. For psychiatric use in older adults, if considered at all, start very low, titrate slowly, and monitor vitals and falls risk closely.🔬Liver Impairment
No specific adult dose adjustment is provided in labeling, but use caution in chronic hepatic impairment. For ER in pediatrics, it has not been studied in significant hepatic impairment; dose adjustments may be necessary. Consider slower titration and lower target doses if side effects emerge.💧Kidney Impairment
Adult labeling does not provide a specific adjustment, and dose adjustment is often unlikely based on pharmacokinetic evidence; however, use caution in chronic renal impairment. Pediatric IR guidance commonly recommends using the lower end of dosing in renal impairment. Hemodialysis clearance is low (~15% of total clearance).